贝伐珠单抗加化疗治疗晚期结肠癌的疗效观察

Efficacy of bevacizumab plus chemotherapy in the treatment of advanced colon

目的 探讨贝伐珠单抗加化疗治疗晚期结肠癌的临床疗效及对细胞免疫功能的影响。方法 选取2018年8月至2021年1月间鞍山市肿瘤医院收治的100例晚期结肠癌患者,采用随机数表法分为研究组和对照组,每组50例。对照组患者采用常规化疗治疗,研究组患者采用贝伐珠单抗+化疗方案治疗,比较两组患者的有效率、免疫功能指标、药物不良反应、无进展生存时间及总生存时间。结果 研究组患者有效率为96.0%,高于对照组的84.0%,差异有统计学意义(P<0.05)。治疗前,两组患者免疫功能指标CD3^(+)和CD4^(+)比较,差异无统计学意义(P>0.05);治疗后,两组患者CD3^(+)和CD4^(+)均降低,且研究组更低,差异均有统计学意义(均P<0.05)。研究组患者药物不良反应为2.0%,低于对照组的16.0%,差异有统计学意义(P<0.05)。研究组患者无进展生存时间和总生存时间均长于研究组,差异均有统计学意义(均P<0.05)。结论 贝伐珠单抗+化疗方案治疗晚期结肠癌患者,可提升治疗有效率,改善免疫功能指标,减少药物不良反应,延长无进展生存时间和总生存时间,建议临床借鉴。

Objective To discuss the efficacy of bevacizumab plus chemotherapy in the treatment of advanced colon cancer and its effect on cellular immune function. Methods A total of 100 patients with advanced colon cancer were selected at Anshan Cancer Hospital between August 2018 and January 2021. They were randomly divided into an experimental group and a control group with 50 patients in each group. The experimental group received bevacizumab plus chemotherapy and the control group received conventional chemotherapy. The effective rate, immune function indexes, adverse drug reactions, progression-free survival, and overall survival were compared between the two groups. Results The efficacy rate was 96.0% in the experimental group which was higher than 84.0% of the control group(P<0.05). Before the treatment, there was no statistically significant difference in the immune function indexes including CD3^(+)and CD4^(+)between the two(P>0.05). After the treatment, the levels of CD3^(+)and CD4^(+)decreased in both groups and the levels were lower in the experimental group than in the control group(all P<0.05). The incidence of adverse drug reactions was 2.0% in the experimental group which was lower than 16.0% of the control group(P<0.05). The progression-free survival and the overall survival in the experimental group than in the control group(all P<0.05). Conclusion Bevacizumab plus chemotherapy can significantly increase treatment efficacy, improve immune function indexes, reduce adverse drug reactions, and prolong progression-free survival and overall survival in patients with advanced colon cancer. It is recommended that it should be used in clinical practice for reference.